The viral vector manufacturing business has become a key pillar of modern biotechnology, enabling the rapid development of gene therapies, cell therapies and improved vaccinations. The growth in the gene therapy pipeline from pharmaceutical and biotechnology companies has created a significant demand for high-quality viral vector production. One of the key strategies for increasing scalability, reducing costs and accelerating commercialisation is to outsource manufacturing to specialist contract development and manufacturing organisations (CDMOs).
The size of the Viral Vector Manufacturing Market was estimated at USD 2.23 billion in 2025 and is expected to reach USD 15.83 billion by 2035, growing at a CAGR of 21.65% during the forecast period 2025-2035, according to industry estimates. The global market is rapidly growing fuelled by increased clinical trial activity, increasing gene therapy approvals and continued investment in manufacturing capacity.
The main developments affecting the business are the expansion of large scale GMP manufacturing facilities and the development of adeno-associated virus (AAV) and lentiviral vector platforms and automated bioprocessing technologies.
Top 7 Leading Vector Manufacturing Companies Transforming the Industry
1. Lonza
Lonza is a leading global viral vector producer providing GMP manufacturing services for gene therapies platforms, vaccines and advanced biologics. The company offers end-to-end development and commercial manufacturing capabilities, supported by state-of-the-art bioreactor technologies and global manufacturing facilities. Further investments in scalable manufacturing technologies have strengthened Lonza’s leadership position in the fast-growing gene therapy industry.
2. Thermo Fisher Scientific
Thermo Fisher Scientific provides a full suite of viral vector manufacturing services, including process development, analytical testing, scale-up and commercial manufacturing. Its global manufacturing network and expertise in regulation allow biotechnology companies to develop gene therapy faster, with consistent product quality. Strategic partnerships further expand the company’s global viral vector manufacturing capabilities.
3. Charles River Laboratories
Charles River Laboratories offers end-to-end viral vector manufacturing to support preclinical development, process optimisation, quality control and GMP manufacturing. With integrated scientific capabilities, the company helps pharmaceutical companies speed up the development of gene therapy while remaining compliant with regulatory standards. Continuous investments in the manufacturing infrastructure further strengthen its position in the global market.
4. Fujifilm Diosynth Biotechnologies
Fujifilm Diosynth Biotechnologies, CDMO, has emerged as a major player in the worldwide large-scale viral vector manufacturing space for gene therapies and vaccines. The company continues to grow its capacity through major investments in state-of-the-art manufacturing facilities, while emphasising high quality process development and commercial scale manufacturing for its global pharmaceutical partners.
5. Catalent
Catalent’s viral vector development and manufacturing solutions support clinical and commercial gene therapy production. The company’s expertise in biologics manufacturing, process optimisation and regulatory compliance enables customers to accelerate product development and improve manufacturing efficiency. Continued investment in gene therapy capabilities builds on its growing industry presence.
6. Merck KGaA (MilliporeSigma)
Merck KGaA, Darmstadt, Germany, known as MilliporeSigma in North America, provides complete viral vector manufacturing technologies, raw materials, analytical services and bioprocessing solutions. The company offers pharmaceutical manufacturers sophisticated production platforms to achieve improved scalability, product consistency and manufacturing efficiency of next generation therapies.
7. Oxford Biomedica
Oxford Biomedica specialises in the development and manufacture of lentiviral vectors for gene and cell therapy applications. The company’s proprietary manufacturing technologies permit the commercial production of advanced therapeutics and adherence to high regulatory standards. Strategic partnerships with major biotechnology companies are driving its global expansion in the viral vector manufacturing sector.
What Is Driving the Future of the Viral Vector Manufacturing Industry?
The rapid development of gene therapy is driving the fastest growth in the market for viral vector manufacturing. The burgeoning research in rare genetic disorders, oncology and regenerative medicine has led to an unprecedented demand for high quality viral vector production. Viral vectors dominate advanced therapeutics and account for more than 70% of active clinical trials in gene therapy today.
Another major trend is the growing utilisation of CDMOs as pharma companies contract out manufacturing to enhance scalability and decrease capital investment. Technological improvements in the production of AAV and lentiviral vectors, automated bioreactors, and high-yield manufacturing platforms support commercial scale operations and increased production efficiency. Other industries’ manufacturing experts are still helping biotech companies innovate through partnerships.
Regionally, North America is at the forefront with its strong biotech infrastructure, tight regulatory environment and extensive clinical trials. The Asia Pacific is anticipated to be the fastest growing region, owing to high government investment in biotechnology infrastructure, manufacturing capacity and gene therapy research to meet the rising global demand.
The Road Ahead
The future of viral vector manufacturing will be driven by the growth of gene therapy pipelines, investment in large-scale manufacturing, and continued technological innovation. Companies with scalable GMP manufacturing, regulatory expertise and cutting edge vector technologies will lead this fast moving industry. As gene therapies move towards commercialisation, viral vector manufacturers will become increasingly important to delivering next-generation therapies to patients around the world.
